ENDPOINTS NEWS2h
Organon's steroid-free cream Vta­ma wins ap­proval in atopic der­mati­tis
Organon won a label expansion for the steroid-free topical cream it picked up from its October acquisition of Dermavant.
ENDPOINTS NEWS3h
FDA stands by mifepri­s­tone safe­ty la­bel in fed­er­al court chal­lenge
The FDA is pushing back against claims that its safety restrictions for the abortion pill mifepristone are “onerous and ...
ENDPOINTS NEWS4h
Bi­cy­cle Ther­a­peu­tics stock sinks fol­low­ing re­lease of topline da­ta, post-hoc analy­ses
Bi­cy­cle Ther­a­peu­tics shared sev­er­al batch­es of da­ta for its bi­cyclic tox­in con­ju­gate in metasta­t­ic urothe­lial ...
ENDPOINTS NEWS3h
McK­in­sey hit with a $650M fine for de­ceiv­ing US about opi­oid con­sult­ing work
McKinsey fined $650M for helping boost OxyContin sales, misleading FDA about conflicts. Ex-partner Martin Elling charged with ...
ENDPOINTS NEWS6h
EMA's com­mit­tee says ex­pand­ed la­bel for Lil­ly's Moun­jaro in­to sleep ap­nea not nec­es­sary
The European Medicines Agency’s human medicines committee (CHMP) handed down 17 recommendations for drug approvals on Friday ...
ENDPOINTS NEWS7h
Bound­less shares dip as it nix­es can­cer as­set, reshuf­fles ex­ecs
Boundless Bio is trimming its oncology pipeline in the wake of disappointing cancer data and switching up its leadership just ...
ENDPOINTS NEWS7h
BeiGene li­cens­es sol­id tu­mor drug, match­es with Ideaya’s com­bo plans
BeiGene acquires MTAP deletion drug SYH2039 from CSPC for $150M, plans combo with BGB-58067, competing with Ideaya's IDE397 ...
ENDPOINTS NEWS7h
CDK4 in­hibitors from BeiGene and Pfiz­er, ALX’s CD47 drug take the stage at SABCS
San Antonio Breast Cancer Conference featured updates on VEGF bispecifics, oral protein degraders, and data from BeiGene, ...
ENDPOINTS NEWS7h
Re­pare plans for Phase 3 en­dome­tri­al can­cer study, sidelin­ing ovar­i­an can­cer
Repare Therapeutics announced that a combination of two targeted drugs resulted in confirmed responses of 19% and 17% in ...
ENDPOINTS NEWS9h
Ab­b­Vie makes an­oth­er small I&I ac­qui­si­tion, buy­ing Nim­ble for $200M
In an attempt to continue its I&I dominance beyond Humira, Skyrizi and Rinvoq, AbbVie is buying up another small autoimmune ...
ENDPOINTS NEWS11h
Xaira hires for­mer Roche ex­ec as CMO; 'Tis the sea­son for re­tire­ments at Al­ny­lam, Re­gen­eron
The billion-dollar AI-focused startup Xaira Therapeutics deepened its C-suite this week, hiring former Roche executive Paulo ...
ENDPOINTS NEWS12h
Af­ter poor lung can­cer da­ta, iTeos drops in­u­padenant to dou­ble down on TIG­IT
Teos Therapeutics halts inupadenant development after poor Phase 2 NSCLC data, and shifts focus to TIGIT program, a combo of ...